11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity

11β-HSD1 has been recognized as a potential therapeutic target for type 2 diabetes. Recent studies have shown that hyperglycemia leads to activation of 11β-HSD1, increasing the intracellular glucocorticoid levels. Excess glucocorticoids may lead to the clinical manifestations of cardiac injury. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Chunpeng, Li, Weixin, Pan, Yong, Khan, Zia A., Li, Jieli, Wu, Xixi, Wang, Yi, Deng, Liancheng, Liang, Guang, Zhao, Yunjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707098/
https://www.ncbi.nlm.nih.gov/pubmed/29221204
http://dx.doi.org/10.18632/oncotarget.22015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707098/
https://www.ncbi.nlm.nih.gov/pubmed/29221204
http://dx.doi.org/10.18632/oncotarget.22015

Ejemplares similares